Eisai hit with Cancer Drugs Fund 'double Whammy'

Eisai has managed to ensure patients in England get access to its end-of-life breast cancer drug Halaven (eribulin), but at a big cost to the company that will have a "direct impact on its activity in the UK". The firm also complained it had been hit with a "double whammy" from the Cancer Drugs Fund after it said it wouldn't be assessing Lenvima (lenvatinib) for thyroid cancer.